tbuckley/cabot-search huggingface dataset:
First report of cancer survivor utilization of comprehensive internet-based survivorship care plans
Authors: C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, L. A. Jacobs, J. M. Metz
Journal: Journal of Clinical Oncology (2008)

20547 Background: Over the past three decades, the number of cancer survivors in the US has more than tripled (MMWR 2004), and these patients remain at risk for late effects resulting from cancer treatment. Survivorship care plans (SCP) have been recommended by the Institute of Medicine to improve quality of care for cancer survivors. Here, we report utilization patterns of the first personalized, web-based SCP tool. Methods: A program for creation of SCP, OncoLife, was designed by oncology physicians and nurses and piloted to cancer survivors prior to launch. OncoLife was then made publicly accessible through OncoLink (www.oncolink.org), a website based at the University of Pennsylvania serving over 3.9 million pages/ month to 385,000 unique IP addresses (Aug 2007). Users responded to queries regarding demographics, diagnosis, and cancer treatment. Individualized, comprehensive reports, including recommendations for future care and screening for late toxicity, second malignancy, fertility, and tumor recurrence were then immediately generated. Results: From 5/07–1/08, 1608 individuals completed OncoLife surveys. Median age at cancer diagnosis was 48 yrs (range 18 - 100), and median current age was 51 yrs (19 - 100+). Users were 87% Caucasian and 71% female; 82% of users had education beyond high school. Breast cancer was the most common primary cancer reported (46%), followed by hematologic (12%), gastrointestinal (GI) (11%), gynecologic (9%) and genitourinary (GU) (6%) malignancies. Of all users, 84% had undergone surgery, 80% received systemic chemotherapy, and 60% were treated with radiotherapy as part of cancer treatment. Conclusions: OncoLife represents the first web-based program for creation of SCP, and patients appear willing to use this type of tool. Most survivors using OncoLife have undergone surgery, chemotherapy and radiation, placing them at risk for treatment-related late effects. Utilization of OncoLife by breast and GI cancer survivors is consistent with their prominence in the survivor population, while use by GU cancer survivors appears to be disproportionately low. Future iterations of OncoLife will include healthcare provider and Spanish versions to expand accessibility and allow greater understanding of the needs of modern cancer survivors. No significant financial relationships to disclose.
Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study.
Authors: R. Delarue, C. Haioun, B. Coiffier, L. Fornecker, M. Fournier, N. Mounier, T. J. Molina, S. Bologna, C. Fruchart, S. Picard, H. Tilly, A. Bosly
Journal: Journal of Clinical Oncology (2011)

9048 Background: Use of erythropoiesis-stimulating agents (ESAs) in chemotherapy-induced anemia is a major issue. Based on recent studies, FDA has modified labeling for ESAs to include a black box warning that limited prescription to pts receiving chemotherapy for non-curative intent. The GELA has conducted a randomized phase III study to evaluate survival impact of Darbepoetin alfa (DA) in pts with DLBCL treated by chemotherapy. We report results of the second interim analysis, with a median follow-up of 44 months Methods: Pts aged from 60 to 80y with DLBCL and aaIPI≥1 were eligible and randomized between two chemotherapy regimens (R-CHOP14 or R-CHOP21) for 8 cycles and between an investigational arm with DA given to maintain Hb level between 13 and 15 g/dL and a conventional arm with usual management of anemia, including transfusion and ESA. Objective was to evaluate efficacy of DA as measured by PFS, EFS, DFS and OS, and to analyze toxicity Results: 602 pts were included, 600 were evaluable; 238 in DA arm and 362 in conventional arm, difference being a consequence of transient stop of randomization asked by French Authorities in 2005. Median age was 70 years. Pts characteristics were similar in both arms. Median baseline Hb level was 12.3 g/dL. During treatment, median Hb level was 11.6 g/dL in DA arm and 10.8 g/dL in conventional arm. Response rate was similar in both arms. Three-year PFS was 66% in DA arm compared to 58% in conventional arm (HR 0.77; CI95%: 0.59-0.99; p=0.04). This difference was also significant for DFS (HR 0.65; CI95%: 0.45-0.92; p=0.02). Despite a trend, OS was not statistically significantly longer in DA arm (HR 0.81; CI95%: 0.60-1.09; p=0.16). In conventional arm, 40% of pts received ESA. Despite no difference in Hb level, PFS was better when comparing pts who receive ESAs with those who did not (HR: 0.73; CI95%: 0.57-0.94; p=0.01). Rate of thrombotic events was higher in DA arm (13%) than in conventional arm (6%). Number of serious adverse events and treatment-related deaths were similar in both arms. Conclusions: Prophylactic use of DA was associated with better PFS. This is the first evidence of positive survival impact of DA in pts receiving chemotherapy for malignancy.
Changes in apparent diffusion coefficient evaluated with diffusion-weighted MRI to predict complete pathologic response after neoadjuvant therapy for rectal cancer: Literature review and meta-analysis.
Authors: Vincenzo Desiato, Alan S Rosman, Elliot Newman, Russell S. Berman, H. Leon Pachter, Marcovalerio Melis
Journal: Journal of Clinical Oncology (2016)

503 Background: A complete pathological response (pCR) is observed in 9-38% of all patients undergoing neo-adjuvant chemo-radiation therapy (CRT) for locally advanced rectal cancer (ARC). Imaging techniques that can reliably assess CRT results may enhance identification of those pCR patients for which surgery may potentially be avoided. Recently, several studies have suggested that diffusion-weighted magnetic resonance imaging (DW-MRI) may predict pathologic response by measuring tumor apparent diffusion coefficient (ADC). ADC can be measured before (pre-ADC) and/or after CRT (post-ADC). Both pre- and post-ADC, as well as the variation between pre- and post-ADC (Δ-ADC) can be used to assess pCR. We aimed to assess the reliability of ADC at predicting pCR in ARC patients treated with CRT. To determine the most effective ADC timing to evaluate pCR. Methods: A systematic review of available literature was conducted to compare all the studies of DW-MRI for identification of pCR after CRT for ARC. For each parameter (pre-ADC, post-ADC and D-ADC) we pooled sensitivity and specificity and calculated the area (AUC) under the summary receiver operating characteristics (sROC) curve. Results: We found 10 prospective and 8 retrospective studies examining correlation of ADC and CRT results. Overall, pCR rate was 25%. Pooled sensitivity, specificity, and AUC were: 0.743, 0.755, and 0.841 for pre-ADC; 0.745, 0.706, and 0.782 for post-ADC; and 0.832, 0.806, and 0.895 for D-ADC. Conclusions: Our meta-analysis confirms that at least 25% of patients with ARC experiences pCR after CRT. DW-MRI is a promising technique for assessment of CRT results and D-ADC appears to be the most effective parameter for prediction of pCR.
A Dual Functional Scaffold Tethered with EGFR Antibody Promotes Neural Stem Cell Retention and Neuronal Differentiation for Spinal Cord Injury Repair
Authors: Bai Xu, Yannan Zhao, Zhifeng Xiao, Bin Wang, Hui Liang, Xing Li, Yongxiang Fang, Sufang Han, Xiaoran Li, Caixia Fan, Jianwu Dai
Journal: Advanced Healthcare Materials (2017)

Neural stem cells (NSCs) transplantation is a promising strategy to restore neuronal relays and neurological function of injured spinal cord because of the differentiation potential into functional neurons, but the transplanted NSCs often largely diffuse from the transplanted site and mainly differentiate into glial cells rather than neurons due to the adverse microenviornment after spinal cord injury (SCI). This paper fabricates a dual functional collagen scaffold tethered with a collagen‐binding epidermal growth factor receptor (EGFR) antibody to simultaneously promote NSCs retention and neuronal differentiation by specifically binding to EGFR molecule expressed on NSCs and attenuating EGFR signaling, which is responsible for the inhibition of differentiation of NSCs toward neurons. Compared to unmodified control scaffold, the dual functional scaffold promotes the adhesion and neuronal differentiation of NSCs in vitro. Moreover, the implantation of the dual functional scaffold with exogenous NSCs in rat SCI model can capture and retain NSCs at the injury sites, and promote the neuronal differentiation of the retained NSCs into functional neurons, and finally dedicate to improving motor function of SCI rats, which provides a potential strategy for synchronously promoting stem cell retention and differentiation with biomaterials for SCI repair.
Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
Authors: P. G. Morris, M. N. Dickler, H. L. McArthur, T. A. Traina, B. Nulsen, R. M. Steingart, H. S. Rugo, L. Norton, C. A. Hudis, C. T. Dang
Journal: Journal of Clinical Oncology (2008)

637 Background: ddAC-paclitaxel (P) is superior to q3w AC-P. Both are associated w/ a <1% incidence of congestive heart failure (CHF). In multicenter studies of adjuvant trastuzumab (T), pt dropout rate after q3w ACx4 was 6.7 % due to asymptomatic declines in LVEF (ALVEF). Per protocol, T was w/held in these pts although the long-term significance of these declines is unknown. There is similar concern for ALVEF for B+AC. We conducted 3 sequential pilot trials of ddAC alone or w/ B and report LVEF changes post AC x4. Methods: Pts w/ HER-2+ BC were eligible for MSKCC trials of ddAC-PT (LVEF ≥55%) and ddAC-PT+lapatinib (LVEF ≥50%). Pts w/ HER-2(-) BC were eligible for a MSKCC+UCSF trial of B+ddAC-nanoparticle albumin-bound P (LVEF > 50%). Pts w/ unstable angina, CHF, or recent MI were excluded. MUGA was repeated after completion of ddACx4. Subsequent therapy (Rx) was determined per protocol guidelines of LVEF. Results: From Jan ‘05 to Dec ‘07, 185 pts were enrolled in 3 trials. Median age was 49yrs (range 27–75). Median LVEF pre-ddAC was 68% (range 53–82%). LVEF post-ddAC is available in 182 pts (98%) (1 pt withdrew consent, 1 progressive disease, 1 died from pneumonia). Median LVEF was unchanged at 68% (range 52–81%). No pt had LVEF decrease to below 50% or developed symptomatic CHF. 1 pt (post ddAC+B) had ALVEF decline>15% from 71 to 53%, which improved to 64% in 4 wks. 5/6 pts w/ LVEF declines of 10–15% had improvement in LVEFs and continued Rx while 1 withdrew consent. Post-ddAC LVEF was similar whether or not pts received B. Conclusions: Previously reported high rates of ALVEF post q3w AC leading to pt dropout were not seen in these 1 and 2 center pilot studies of ddAC or ddAC+B. Possible explanations are that 1) ddAC is safer than q3wAC in the short-term, 2) consistent equipment and interpretation causes fewer false positive declines in LVEF and/or 3) unplanned pt selection avoided ‘at risk’ pts. Long-term follow-up continues. Changes in LVEF post ddAC and ddAC+B Change in LVEF All Patients N (%) ddAC alone N (%) ddAC + B N (%) Total Patients 182 104 78 decrease > 15% 1 (0.5) 0 1 (1.3) decrease 10–15% 6 (3.3) 2 (1.9) 4 (5.1) decrease 5–9% 28 (15.4) 19 (18.3) 9 (11.5) decrease <5% 48 (26.4) 27 (26.0) 21 (26.9) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Abraxis Oncology, Amgen, Genentech™ BioOncology, GlaxoSmithKline Abraxis Oncology, Amgen, Genentech™ BioOncology, GlaxoSmithKline Abraxis Oncology, Amgen, Genentech™ BioOncology, GlaxoSmithKline
Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.
Authors: Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Annalisa Citro, Paola Brasca, Luigi Montalbetti, Patrizia Zappasodi, Federica Cocito, Marzia Varettoni, Mario Lazzarino, Enrica Morra
Journal: Blood (2009)
Quality of life (QoL) by response: An interim analysis of patients (pts) with squamous (SCC) NSCLC treated with <i>nab</i>-paclitaxel/carboplatin (<i>nab</i>-P/C) induction therapy in the phase III ABOUND.sqm study.
Authors: Corey J. Langer, Vera Hirsh, Katayoun Amiri, Amy Ko, Jeanna L. Knoble, Melissa Lynne Johnson, Robert M. Jotte, Michael McCleod, Teng Jin Ong, Ray D. Page, David R. Spigel, Howard Jack West
Journal: Journal of Clinical Oncology (2016)

63 Background: The correlation of radiological response and pt-reported outcomes (PROs) in advanced NSCLC remains underreported. This interim analysis evaluated QoL by response (RECIST v1.1) in SCC NSCLC pts treated with nab-P/C during the induction part of the ABOUND.sqm study. Methods: In the ongoing phase III ABOUND.sqm study, pts with advanced SCC NSCLC are treated with first-line nab-P 100 mg/m 2 d 1, 8, 15 and C AUC 6 mg•min/mL d 1 (21-d cycles) for 4 cycles (induction). Pts not progressing are randomized 2:1 to maintenance nab-P 100 mg/m 2 d 1 and 8 of each 21-d cycle + best supportive care (BSC) or BSC alone until progression. The primary endpoint is PFS from randomization to maintenance. QoL, an exploratory endpoint, was assessed with predefined PRO instruments, LCSS and EQ-5D-5L, on d 1 of each cycle. Pts with a radiological CR/ PR are considered responders (R) in this analysis (57% of evaluable pts). As the study is ongoing, this pre-planned analysis included QoL and tumor response data that were reported up to the cutoff date. Results: Baseline (BL) characteristics were similar for Rs (n = 73) and non-Rs (n = 55). Over 80% of pts completed BL + ≥ 1 post-BL PRO assessments. For LCSS, average total score and symptom burden index improved during induction chemotherapy; a higher percentage of Rs vs non-Rs had clinically meaningful improvements (≥ 10 mm [VAS]) from BL in composite LCSS cough, shortness of breath, &amp; hemoptysis (56% vs 38%). Of pts reporting BL EQ-5D-5L dimension problem(s), a higher percentage of Rs vs non-Rs reported complete resolution at least once during treatment (Table). Conclusions: These results indicate that Rs and non-Rs maintained/improved QoL during induction therapy with nab-P/C. Rs appeared to have greater improvements in LCSS and EQ-5D-5L. Radiological response translates into meaningful QoL improvement. Clinical trial information: NCT02027428. [Table: see text]
Prediction of metastatic pancreatic cancer patients’ survival using both host immunity and tumor metabolic activity.
Authors: Younak Choi, Do-Youn Oh, Hyunkyung Park, Tae Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Journal: Journal of Clinical Oncology (2016)

411 Background: Host antitumor immunity measured by neutrophil-lymphocyte ratio (NLR) is reported to be associated with prognosis of cancer patients. Standard uptake value (SUV)by 18 F-FDG PET represents the metabolic activity of tumor itself. The correlation of host immunity and tumor metabolic activity has not been studied. We investigate the association of these two factors and evaluate their roles in prediction of overall survival (OS) in metastatic pancreatic cancer (MPC) patients who receive palliative chemotherapy. Methods: We reviewed 396 MPC patients receivingpalliative chemotherapy. NLR was obtained before initiation of chemotherapy and after 1 st cycle of chemotherapy. In 118 patients who were evaluated with 18 F-FDG PET before initiation of chemotherapy (PET cohort), maximum SUV (SUVmax) was collected. Cut-offs for each variable were determined by ROC curve. Results: In multivariate analysis, higher NLR was associated with worse OS ( &lt; 2.5, 9.0 m; 2.5-4.4, 7.2 m; ≥ 4.5, 3.9 m; p&lt; 0.001). Reduction of NLR after 1 st cycle of chemotherapywas associated with betterOS (8.0 m vs 6.1 m; HR 0.653; p&lt; 0.001). We made the risk scoring model considering both NLR (score 0, NLR &lt; 2.5; score 1, 2.5 ≤ NLR &lt; 4.5; score 2, NLR ≥ 4.5) and ΔNLR(score 0:ΔNLR &lt; 0; score 1: ΔNLR ≥ 0), which identified 4 risk groups with different prognosis (group with risk score 0 vs 1 vs 2 vs 3: OS 9.7 vs 7.9 vs 5.7 vs 2.6 months; HR 1 vs 1.329 vs 2.137 vs 7.915, respectively; P &lt; 0.001). In PET cohort (118 patients), NLR and SUVmax were independent prognostic factors for OS. The risk model considering both NLR (score 0, NLR &lt; 2.5; score 1, 2.5 ≤ NLR &lt; 4.5; score 2, NLR ≥ 4.5) and SUVmax (score 0:SUVmax &lt; 4.5; score 1: SUVmax ≥ 4.5), which define 4 risk groups with different OS. (group with risk score 0 vs 1 vs 2 vs 3: OS 11.8 vs 9.8 vs 7.2 vs 4.6 months; HR 1 vs 1.536 vs 2.958 vs 5.336, respectively; P &lt; 0.001). Conclusions: NLR and SUVmax as simple parameters of host antitumor immunity and tumor metabolic activity, respectively, have significant impacts on the survival of metastatic pancreatic cancer patients independently. Consideration of both aspects allows more precise prediction of patients’ prognosis.
Concomitant radiotherapy (RT) with docetaxel for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Authors: N. Fuente, J. M. Mañé, I. Rubio, S. Carrera, A. Martínez-Bueno, G. López de Argumedo, J. Ferreiro, G. Abón, P. Garrido, G. López-Vivanco
Journal: Journal of Clinical Oncology (2008)

7581 Background: Platinum-based chemotherapy and radiotherapy is the standard treatment for LA-NSCLC. Concurrent chemoradiotherapy appears to improve the results. We evaluated efficacy and safety of concomitant docetaxel with radiotherapy in stage IIIA/B unresectable LA-NSCLC. Methods: From August-04 to March-07, 54 patients with unresectable LA-NSCLC received docetaxel 20mg/m2/week concurrently with RT. All patients had received induction platinum-based chemotherapy (maximum 4 courses). Radiation therapy was given using linear accelerator, planning target volume for 3D conformal and standard fraction 60–65 Gy. Results: Mean age 60 y (range 44–76). Male/female 50/4. PS 0/1/2: 24/28/2. Squamous cell 50%, adenocarcinoma 24% and undifferentiated 14% and others 12%. Stage IIIA/IIIB: 11/43. Median weekly docetaxel administration was 6 and median RT dose received was 58 Gy. Toxicity (grade 2/3/4): esophagitis: 16/10/1, weight lost: 7/2/0, pneumonitis: 0/2/3, astenia: 3/4/0, infection: 1/3/1, anemia: 2/1/0, neutropenia: 0/0/1, thrombopenia: 0/0/1. There were 3 toxic deaths (5.5%): 1 radiation esophagitis and 2 radiation pneumonitis. One patient needed esophageal dilation due to stenosis. Overall response rate was 37%: 7/54 (13%) CR, 13/54 (24%) PR and 19/54 patients (35%) SD. A resection was subsequently done in one patient after D-RT. From the D-RT start, median progression-free survival was 31.4 weeks (95% CI 20–43) and median overall survival was 55 weeks (95% CI 32–78). Median overall survival since the beginning of induction chemotherapy was 68.4 weeks (95% CI 52–85). Conclusions: Weekly docetaxel concurrent with RT is an active treatment for LA-NSCLC but with significant toxicity. Esophagitis and pneumonitis are the most severe adverse events. No significant financial relationships to disclose.
<i>HSD3B1</i> and resistance to androgen deprivation therapy in prostate cancer.
Authors: Jason W.D. Hearn, Ghada AbuAli, Cristina Magi-Galluzzi, Chandana A. Reddy, Kai-Hsiung Chang, Eric A. Klein, Nima Sharifi
Journal: Journal of Clinical Oncology (2015)

156 Background: The somatic mutation HSD3B1(1245A&gt;C) has been mechanistically linked to castration-resistant prostate cancer by encoding a mutant enzyme that augments intratumoral dihydrotestosterone synthesis. Given the HSD3B1(1245C) allele is also frequently found in the germline, we hypothesized men inheriting this variant allele would exhibit resistance to androgen deprivation therapy (ADT), as manifested by worse clinical outcomes. Methods: We used a prospectively maintained prostate cancer registry to identify men treated with ADT for biochemical failure in the post-prostatectomy setting who were without evidence of metastatic disease at the time of ADT initiation. We analyzed progression-free survival, distant metastasis-free survival, and overall survival according to HSD3B1 genotype using Kaplan-Meier methods. Cox proportional hazards regression was performed to evaluate potential gene-dosage effects, with homozygous wild-type men serving as the reference group. Demographic and treatment characteristics were compared across genotypes to assess for possible confounders using Fisher’s exact test and Kruskal-Wallis analysis of variance. Results: Of 118 men genotyped, 37% were homozygous wild-type, 53% were heterozygous, and 10% were homozygous variant. Demographic and treatment characteristics did not differ across groups. Median progression-free survival diminished as a function of the number of variant alleles inherited (6.6 years in homozygous wild-type men, 4.1 years in heterozygotes, and 2.5 years in homozygous variant men; P=0.01). Median distant metastasis-free survival likewise decreased according to the number of variant alleles inherited (9.1 years in homozygous wild-type men, 6.8 years in heterozygotes, and 3.6 years in homozygous variant men; P=0.01). Finally, overall survival also diminished with the number of variant alleles inherited (5-year and 10-year overall survival: 82% and 55% in homozygous wild-type men, 74% and 35% in heterozygotes, and 58% and 0% in homozygous variant men; P=0.006). Conclusions: Inheritance of the variant HSD3B1(1245C) allele that enhances dihydrotestosterone synthesis may predict resistance to ADT for prostate cancer. These findings require validation.
The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer.
Authors: Lorenzo Tosco, Hendrik Van Poppel, Thomas Van den Broeck, Patrick Bastian, Alberto Briganti, Felix K. Chun, Paolo Gontero, Chien Yeh Hsu, R. Jeffrey Karnes, Giansilvio Marchioro, Rafael Sanchez-Salas, Martin Spahn, Bertrand Tombal, Henk Van Der Poel, Steven Joniau
Journal: Journal of Clinical Oncology (2014)

114 Background: High-risk prostate cancer (HRPC) is a challenging disease and the role of surgery is often considered in the context of a multimodal approach. The indication for adjuvant therapy after surgery for HRPC patients who have specimen-confined disease (R0, pN0, &lt;pT3b) is still difficult. The current study aims to analyze postoperative pathological features which help to predict CSS in specimen-confined HRPC and thus may aid in the decision to administer adjuvant EBRT or ADT. Methods: From a multi-institutional retrospective cohort of 5876 HRPC patients treated by radical prostatectomy and pelvic lymph node dissection, 1391 patients with specimen-confined disease were selected. Following surgery, adjuvant EBRT and/or ADT were delivered according to institutional protocols. Patients were subdivided into four groups according to pT stage (pT≥3 and pT&lt;3) and final Gleason score (GS≥8 and GS&lt;8). Kaplan-Meier plots with log-rank tests and a Cox proportional hazards model were applied to study CSS. All significance levels were set at 0.05. MedCalc was used for all statistical analyses. Results: Median age was 65 years (43-84). Of all patients, 346 (24.9%) had GS≥8 and 794 (57.1%) had pT≥3 at definitive histopathology. Patients were classified into COMBO groups: C1 (478; 34.4%; GS&lt;8,pT&lt;3), C2 (567; 40.8%; GS&lt;8, pT≥3), C3 (119; 8.6%; GS≥8, pT&lt;3), C4 (227; 16.3%; GS≥8, pT≥3). Adjuvant EBRT and ADT, respectively, were delivered in C1 2%/2%, C2 15%/22%, C3 3%/10%, C4 18%/25%. Kaplan Meier plots demonstrated statistically different 10-yr CSS between groups: C1 97.4%, C2 95.2%, C3 89.9% and C4 84.4% (p&lt;0.0001). COMBO groups were also compared using a Cox model and results are shown in the Table. Conclusions: COMBO groups demonstrated to be able to subdivide specimen-confined HRPC into 4 demarcated groups with significantly different CSS. This subdivision could be considered an easy-to-use tool which can help for counseling patients for adjuvant treatment strategies. [Table: see text]